Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis
National Institutes of Health · Marks and Spencer (United Kingdom) · +6 more institutions
Abstract
BACKGROUND: The prognosis and treatment of the 2 main types of cardiac amyloidosis, immunoglobulin light chain (AL) and transthyretin (ATTR) amyloidosis, are substantially influenced by cardiac involvement. Cardiovascular magnetic resonance with late gadolinium enhancement (LGE) is a reference standard for the diagnosis of cardiac amyloidosis, but its potential for stratifying risk is unknown. METHODS AND RESULTS: Two hundred fifty prospectively recruited subjects, 122 patients with ATTR amyloid, 9 asymptomatic mutation carriers, and 119 patients with AL amyloidosis, underwent LGE cardiovascular magnetic resonance. Subjects were followed up for a mean of 24±13 months. LGE was performed with phase-sensitive…
Citation impact
- FWCI
- 23.19
- Percentile
- 100%
- References
- 27
Authors
24- MFMarianna FontanaCorresponding
National Institutes of Health, Marks and Spencer (United Kingdom), University of Pittsburgh, University of Bristol, National Heart Lung and Blood Institute, NIHR Bristol Cardiovascular Biomedical Research Unit, University College London
- SPSilvia Pica
National Institutes of Health, Marks and Spencer (United Kingdom), University of Pittsburgh, University of Bristol, National Heart Lung and Blood Institute, University College Hospital at Westmoreland Street, NIHR Bristol Cardiovascular Biomedical Research Unit, University College London
- PRPatricia Réant
National Institutes of Health, Marks and Spencer (United Kingdom), University of Pittsburgh, University of Bristol, National Heart Lung and Blood Institute, University College Hospital at Westmoreland Street, NIHR Bristol Cardiovascular Biomedical Research Unit, University College London
- AAAmna Abdel‐Gadir
National Institutes of Health, Marks and Spencer (United Kingdom), University of Pittsburgh, University of Bristol, National Heart Lung and Blood Institute, University College Hospital at Westmoreland Street, NIHR Bristol Cardiovascular Biomedical Research Unit, University College London
- TAThomas A. Treibel
National Institutes of Health, Marks and Spencer (United Kingdom), University of Pittsburgh, University of Bristol, National Heart Lung and Blood Institute, University College Hospital at Westmoreland Street, NIHR Bristol Cardiovascular Biomedical Research Unit, University College London
Topics & keywords
- Medicine
- Cardiac amyloidosis
- Amyloidosis
- Hazard ratio
- Ejection fraction
- Magnetic resonance imaging
- Transthyretin
- Cardiology
- Good health and well-being